The objective of the study was to determine the impact of high doses of corticosteroids (equal or greater than 1 mg/kg of methylprednisolone: HDCT) in critically ill COVID-19 patients with nonresolving acute respiratory distress syndrome (ARDS) previously treated with dexamethasone.
Prospective observational cohort study of patients with nonresolving ARDS related to COVID-19. Comparing those who received HDCT with those who did not. Primary outcome: 90-day mortality.
11 ICUs in the Great Paris area from September 2020 to February 2021.
383 patients included (59 in HDCT group, 324 in no HDCT group).
At day 90, 51% of HDCT group and 35.8% of no HDCT group patients had died. HDCT was significantly associated with higher 90-day mortality.
🔍 Summary: High doses of corticosteroids (HDCT) in critically ill COVID-19 patients with nonresolving ARDS, previously treated with dexamethasone, were linked to a higher 90-day mortality rate. However, HDCT did not increase the risk of ventilator-associated pneumonia.